InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,426.87
(
-0.67%
)
US TECH 100
18,249.20
(
-1.65%
)
Dow Jones
40,638.57
(
0.24%
)
Brent Oil
78.29
(
-1.09%
)
Bitcoin
65,776.70
(
-1.57%
)
Post# of 4975360
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

WizardofOdds1357

Send PM Follow Ignore
Followers 156
Posts 477
Boards Moderated 0
Alias Born 08/12/2014

WizardofOdds1357

Re: None

Monday, 08/15/2016 9:10:33 AM

Monday, August 15, 2016 9:10:33 AM

Post# of 4975360
$ARTH -NEWS successfully met the objectives of its recently completed single-center, randomized, single-blind prospective clinical study (NCT 02704104) of the AC5 Topical Hemostatic Device in skin lesion patients with bleeding wounds. This was the first study assessing the safety and performance of AC5 in humans.
http://www.stockwatch.com/News/Item.aspx?bid=U-i1273018-U%3aARTH-20160815&symbol=ARTH®ion=U
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up